| Literature DB >> 20171517 |
John P Kirkpatrick1, Albert J van der Kogel, Timothy E Schultheiss.
Abstract
Dose-volume data for myelopathy in humans treated with radiotherapy (RT) to the spine is reviewed, along with pertinent preclinical data. Using conventional fractionation of 1.8-2 Gy/fraction to the full-thickness cord, the estimated risk of myelopathy is <1% and <10% at 54 Gy and 61 Gy, respectively, with a calculated strong dependence on dose/fraction (alpha/beta = 0.87 Gy.) Reirradiation data in animals and humans suggest partial repair of RT-induced subclinical damage becoming evident about 6 months post-RT and increasing over the next 2 years. Reports of myelopathy from stereotactic radiosurgery to spinal lesions appear rare (<1%) when the maximum spinal cord dose is limited to the equivalent of 13 Gy in a single fraction or 20 Gy in three fractions. However, long-term data are insufficient to calculate a dose-volume relationship for myelopathy when the partial cord is treated with a hypofractionated regimen. Copyright 2010 Elsevier Inc. All rights reserved.Entities:
Mesh:
Year: 2010 PMID: 20171517 DOI: 10.1016/j.ijrobp.2009.04.095
Source DB: PubMed Journal: Int J Radiat Oncol Biol Phys ISSN: 0360-3016 Impact factor: 7.038